Drug Information

Drug (ID: DG00984) and It's Reported Resistant Information

• Name: 2-hydroxy-5-fluoropyrimidine
• Synonyms: 2022-78-8; 5-fluoropyrimidin-2-ol; 5-Fluoropyrimidin-2(1H)-one; 5-Fluoro-2-hydroxypyrimidine; 5-Fluoropyrimidin-2-one; 2-Hydroxy-5-fluoropyrimidine; 214290-48-9; 5-fluoro-1H-pyrimidin-2-one; 5-Fluoro-2-pyrimidinol; 2(1H)-Pyrimidinone, 5-fluoro-; 5-fluoro-2-pyrimidone; UNII-1VXI7T1BI5; 5-fluoro-pyrimidin-2-ol; 1VXI7T1BI5; SMR000449315; 2-Pyrimidinol, 5-fluoro- (9CI); 5-FP; NSC529069; NSC 529069; 5-fluoropyrimid-2-one; 5-Fluro-2-pyrimidone; 5-fluoropyrimidine-2-one; 2-Pyrimidinol, 5-fluoro-; MLS000758251; MLS001424161; SCHEMBL309070; AMY113; CHEMBL4303165; 2-Pyrimidinol,5-fluoro-(9CI); DTXSID90174067; CHEBI:125539; HMS2051J14; HMS3393J14; 0373AB; 5-Fluoro-2-hydroxypyrimidine, 97%; MFCD00223678; ZB1820; ZINC16697945; 5-fluoro-1,2-dihydropyrimidin-2-one; AKOS006347205; AKOS016004426; CCG-101035; CS-W008541; GS-6508; NC00285; NSC-529069; SB56948; SB57746; AC-26618; FT-0649189; 2(1H)-Pyrimidinone, 5-fluoro- (8CI)(9CI); A879769; J-013132; Q27216155
• Indication:
  In total 1 Indication(s)
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (2 diseases)
  Brain cancer [ICD-11: 2A00]; [1]
  Ovarian cancer [ICD-11: 2C73]; [1]
• Target: Human Deoxyribonucleic acid (hDNA); NOUNIPROTAC; [1]
• Formula: C4H3FN2O
• IsoSMILES: C1=C(C=NC(=O)N1)F
• InChI: 1S/C4H3FN2O/c5-3-1-6-4(8)7-2-3/h1-2H,(H,6,7,8)
• InChIKey: HPABFFGQPLJKBP-UHFFFAOYSA-N
• PubChem CID: 101498
• ChEBI ID: CHEBI:125539
• TTD Drug ID: D02ONT
• DrugBank ID: DB01357

Type(s) of Resistant Mechanism of This Drug

  RTDM: Regulation by the Disease Microenvironment

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Brain cancer [ICD-11: 2A00]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Regulation by the Disease Microenvironment (RTDM)

Key Molecule: L1 cell adhesion molecule (L1CAM) [1]

• Molecule Alteration: Expression; Down-regulation
• Resistant Disease: Glioblastoma [ICD-11: 2A00.02]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell migration; Activation; hsa04670
• In Vitro Model: MDCK cells; Kidney; Canis lupus familiaris (Dog) (Canis familiaris); CVCL_0422
• Experiment for Molecule Alteration: Puromycin selection and monitored regularly for the maintenance of L1 silencing assay
• Experiment for Drug Resistance: Migration assay
• Mechanism Description: With OVCAR3 cells treated with anagrelide, 2-hydroxy-5-fluoropyrimidine and mestranol , the gap width closure was seen from 48 h onward at all concentrations tested. Similar results were obtained with U251 cells, and L1's metastatic potential is further evidenced by its promotion of epithelial-mesenchymal transition, endothelial cell transcytosis and resistance to chemo- and radiotherapy.

Ovarian cancer [ICD-11: 2C73]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Regulation by the Disease Microenvironment (RTDM)

Key Molecule: L1 cell adhesion molecule (L1CAM) [1]

• Molecule Alteration: Expression; Down-regulation
• Resistant Disease: Ovarian cancer [ICD-11: 2C73.0]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell migration; Activation; hsa04670
• In Vitro Model: 22RV1 cells; Prostate; Homo sapiens (Human); CVCL_1045
• Experiment for Molecule Alteration: Puromycin selection and monitored regularly for the maintenance of L1 silencing assay
• Experiment for Drug Resistance: Migration assay
• Mechanism Description: With OVCAR3 cells treated with anagrelide, 2-hydroxy-5-fluoropyrimidine and mestranol , the gap width closure was seen from 48 h onward at all concentrations tested. Similar results were obtained with U251 cells, and L1's metastatic potential is further evidenced by its promotion of epithelial-mesenchymal transition, endothelial cell transcytosis and resistance to chemo- and radiotherapy.

References

• Ref 1: Antagonistic L1 Adhesion Molecule Mimetic Compounds Inhibit Glioblastoma Cell Migration In Vitro .Biomolecules. 2022 Mar 12;12(3):439. doi: 10.3390/biom12030439. 10.3390/biom12030439